World Health Organization Issues Concern Over Acute Lack of Weight-Loss Injections
Less than a tenth of people who could benefit from obesity jabs such as Wegovy have access to them, states the WHO as it releases its inaugural guidance on the medications.
Considering more than one billion people worldwide currently classified as obese, it is urging increased and just access to these injectable treatments.
Based on forecasts, more than two billion will be obese by 2030 without intervention.
"Our new guidelines affirms that excess weight is a long-term condition that can be managed with holistic and ongoing treatment," stated the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and distribution challenges are significant barriers to broad access to the jabs that can assist patients in reducing substantial body mass, notes the organization.
GLP-1 Therapy Supply Crisis
Even in the present most optimistic case, the manufacturing of GLP-1 therapies could only cover approximately 100 million people – under 10% of eligible patients, according to the WHO.
The guideline encourages countries and companies to widen availability, via strategies such as licensing agreements.
The intellectual property rights on the active ingredient – the core component of the drug Wegovy – is set to lapse in several countries in 2026.
The Way Weight-Loss Drugs Operate
GLP-1 drugs imitate a body's own hormone to delay gastric emptying, suppress the appetite and boost satiety so individuals eat less.
Individuals typically see weight reduction after several weeks of commencing the weekly injections.
Research suggests users may regain a significant portion within a year of stopping the drug, when their typical hunger resume.
To be carrying excess weight raises your likelihood for experiencing health problems, like diabetes, cardiovascular issues, stroke, and some malignancies.
Obesity concerns individuals in every country and was linked to over three and a half million deaths worldwide in 2024, as per the health agency.
